VRTX · 8-K · 20260707PR296710

Acquisition / Partnership / Divestiture

VERTEX PHARMACEUTICALS INC / MA · 2026-07-07 · Importance 71 · Surprise 60 · Contradicted

Vertex agreed to acquire all outstanding shares of Crinetics Pharmaceuticals for $85 per share in cash, representing a $10.0 billion equity valuation and $8.8 billion net of cash. The transaction was unanimously approved by both companies’ boards and is expected to close in the third quarter of 2026, subject to Crinetics stockholder approval and other closing conditions. Vertex expects the acquisition to add a fifth revenue-growth pillar, accelerate launches and pipeline development, and provide approximately $5 billion of combined peak annual revenue potential from Crinetics’ late-stage assets. The transaction is expected to become accretive to non-GAAP operating income in 2029.

Key facts

• Vertex to acquire Crinetics for $85/share in cash. source
• Transaction values Crinetics at $10.0B equity valuation, $8.8B net of cash. source
• The expected close of the Transaction is Q3:26, subject to Crinetics’ shareholder approval and other closing conditions. source
• The acquisition of Crinetics was unanimously approved by the Boards of both companies. source

Impact estimates